Aaj TV News

BR100 4,855 Increased By ▲ 19 (0.39%)
BR30 24,780 Increased By ▲ 335 (1.37%)
KSE100 45,903 Increased By ▲ 177 (0.39%)
KSE30 19,153 Increased By ▲ 133 (0.7%)

Yesterday, the American biotechnology company Moderna announced the final results of the efficacy trial data of 30,000 volunteers- including high-risk groups like the healthcare providers and elderly- for its vaccine candidate in a press release.

The findings are as follows:

  • 15,000 people received the actual vaccine while the other participants got placebo injections. No serious side effects were reported.

  • Only 11 people who received two doses of the vaccine developed COVID-19 symptoms after being infected with the pandemic coronavirus, versus 185 symptomatic cases in a placebo group.

That is the efficacy of an impressive 94.1%, exceeding even the expectations of scientists conducting the trial.

  • Moderna’s candidate had 100% efficacy against severe disease. There were zero such COVID-19 cases among those vaccinated, but 30 in the placebo group. This is perhaps even more pleasantly surprising development.

It must be noted that full trial data has not been released yet, the company says that it will be published in a peer-reviewed journal soon.

Due to the exceedingly optimistic findings of the Moderna coronavirus vaccine, the biotech company is filing for the United States and European emergency regulatory approval so that it can be recommended for widespread use.

Moderna is the third vaccine to show encouraging results during trials. Other being AstraZeneca and Pfizer vaccines. The positive results of vaccine trials are welcoming news for the world as the number of coronavirus cases is increasing rapidly across the globe and every nation is desperate to find a cure and/or preventive medicine for this deadly disease as soon as possible.